VBIV VBI Vaccines

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.
Company profile
Ticker
VBIV
Exchange
Website
CEO
Jeffrey R. Baxter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LEVON RESOURCES LTD, LEVON RESOURCES LTD., SciVac Therapeutics Inc.
SEC CIK
Corporate docs
VBIV stock data
()
News
VBI Vaccines Announces Data Form Phase 1b/2a Study Of Its Hepatitis B Immunotherapeutic Candidate Showing Robust HBV Specific T Cell Responses In ≥ 50% Of Evaluable Patients
12 Apr 21
CEPI, VBI Vaccines Collaborate To Develop COVID-19 Vaccine Candidates Against Variants
10 Mar 21
Coalition for Epidemic Preparedness Innovations To Provide Up To $33M To Support Advancement OF VBI Vaccines' VBI-2905 Vaccine Candidate
10 Mar 21
VBI Vaccines Moves Forward With Prophylactic COVID-19 Vaccine Study
9 Mar 21
VBI Vaccines Initiates Enrollment In Adaptive Phase 1/2 Study Of Prophylactic COVID-19 Vaccine Candidate, VBI-2902
9 Mar 21
Investment data
Securities sold
Number of investors
Calendar
2 Mar 21
18 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 93.83M | 93.83M | 93.83M | 93.83M | 93.83M | 93.83M |
Cash burn (monthly) | 444.33K | (positive/no burn) | 5.12M | 3.94M | 5.5M | 3.92M |
Cash used (since last report) | 1.61M | n/a | 18.52M | 14.25M | 19.89M | 14.18M |
Cash remaining | 92.22M | n/a | 75.3M | 79.57M | 73.94M | 79.64M |
Runway (months of cash) | 207.5 | n/a | 14.7 | 20.2 | 13.4 | 20.3 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Jan 21 | Baxter Jeff | Option (Right to Buy Common Shares) Common Shares | Grant | Aquire A | No | No | 3.15 | 1,000,000 | 3.15M | 1,000,000 |
27 Jan 21 | Steven Gillis | Option (Right to Buy Common Shares) Common Shares | Grant | Aquire A | No | No | 3.15 | 100,000 | 315K | 100,000 |
27 Jan 21 | Anderson David Evander | Option (Right to Buy Common Shares) Common Shares | Grant | Aquire A | No | No | 3.15 | 500,000 | 1.58M | 500,000 |
27 Jan 21 | McNulty Christopher | Option (Right to Buy Common Shares) Common Shares | Grant | Aquire A | No | No | 3.15 | 500,000 | 1.58M | 500,000 |
27 Jan 21 | Joanne Cordeiro | Option (Right to Buy Common Shares) Common Shares | Grant | Aquire A | No | No | 3.15 | 75,000 | 236.25K | 75,000 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
47.9% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 123 |
Opened positions | 34 |
Closed positions | 24 |
Increased positions | 48 |
Reduced positions | 25 |
13F shares |
Current |
---|---|
Total value | 431.02M |
Total shares | 121.55M |
Total puts | 934.9K |
Total calls | 531.4K |
Total put/call ratio | 1.8 |
Largest owners |
Shares | Value |
---|---|---|
Perceptive Advisors | 55.04M | $151.37M |
STT State Street | 22.29M | $61.31M |
BLK Blackrock | 13.18M | $36.23M |
Vanguard | 5.51M | $15.14M |
Geode Capital Management | 2.96M | $8.15M |
NTRS Northern Trust | 2.1M | $5.77M |
Cambridge Investment Research Advisors | 1.65M | $4.52M |
GAM General American Investors | 1.64M | $4.5M |
Charles Schwab Investment Management | 1.4M | $3.86M |
Susquehanna International | 1.29M | $3.56M |
Financial report summary
?Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abrogating, accuracy, Africa, AgreementSM, alia, amalgamation, Ankura, Area, AstraZeneca, ATM, baseline, BCF, BCPIA, Biden, binding, biodefense, Biomedical, BioNTech, Braga, brand, Britain, broaden, BV, CDMO, circulation, client, collateral, coping, copy, COVID, CureVac, Damian, deadly, dedicated, deep, deployment, difficulty, disputed, dissipate, EC, ECDRP, EEA, encourage, explanatory, feature, footprint, formidable, Gag, globe, Great, hamper, hearing, hundred, HVB, Iceland, ideal, IIa, importantly, inadvertent, infiltration, innate, InVentiv, IRAP, Ireland, isolated, Johnson, leadership, lesser, Liechstenstein, load, longevity, Majesty, Medicago, MHRA, Minister, Minster, morphologically, mutated, necessitated, Northern, Norway, Novavax, nucleotide, obesity, obligor, opponent, Pacific, pandemic, paragraph, particulate, PDUFA, precautionary, Preceptive, prefusion, prepaid, prepayment, prime, prioritize, procurement, PRs, pseudoprogression, pursuit, Queen, reactive, readily, reallocate, receptor, recession, rectification, redacted, refinanced, relaxed, remediation, reperfoming, reperforming, repetitive, Resilience, resurgence, RNA, route, running, satisfactory, SE, shelf, shrinkage, SIF, signatory, skill, SNO, Sorbonne, specialist, Speed, spike, spontaneously, spread, subsided, suggesting, symptomatic, Therapure, today, topline, transmissibility, transmit, Trust, Twinrix, UK, unadjuvanted, Universit, Universite, unprecedented, unrealized, unreasonably, unredacted, unregistered, Valneva, variant, verified, vouching, Warp, worsening
Removed:
Adam, aseptic, billion, brain, Buckley, Canaccord, cap, capped, comparative, content, deciding, display, dissolved, distribute, epithelial, exemption, filling, Florida, Genuity, geometric, immunologic, index, induced, inInternal, leveraging, LIBOR, manager, membrane, Miami, obliging, OPKO, outbound, package, percent, periodically, pool, preclinical, presidential, purification, reclassified, recommended, remeasured, reorganization, repurchased, resigned, secondary, statuary, synthetically, ticker, traditional, upstream, USA
Financial reports
10-K
2020 FY
Annual report
2 Mar 21
10-Q
2020 Q3
Quarterly report
2 Nov 20
10-Q
2020 Q2
Quarterly report
31 Jul 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
5 Mar 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
1 May 19
10-K
2018 FY
Annual report
25 Feb 19
10-Q
2018 Q3
Quarterly report
9 Nov 18
Current reports
8-K
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
12 Apr 21
8-K
VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference
15 Mar 21
8-K
VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902
10 Mar 21
8-K
VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021
2 Mar 21
8-K
VBI Vaccines to Present at the Raymond James 42nd Annual Institutional Investors Conference
1 Mar 21
8-K
VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
2 Feb 21
8-K
VBI Vaccines Announces Progress of Coronavirus Vaccine Program
21 Jan 21
8-K
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s
15 Jan 21
8-K
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing
23 Dec 20
8-K
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
7 Dec 20
Registration and prospectus
S-8
Registration of securities for employees
31 Jul 20
S-3ASR
Automatic shelf registration
31 Jul 20
D
$4.7M in equity / options / securities to be acquired, sold $4.7M, 1 investor
27 May 20
D
$1.06M in options / securities to be acquired, sold $1.06M, 61 investors
30 Apr 20
424B5
Prospectus supplement for primary offering
24 Apr 20
424B5
Prospectus supplement for primary offering
21 Apr 20
424B5
Prospectus supplement for primary offering
20 Sep 19
424B5
Prospectus supplement for primary offering
18 Sep 19
424B5
Prospectus supplement for primary offering
16 Dec 18
424B5
Prospectus supplement for primary offering
12 Dec 18
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
10 May 19
DEF 14A
Definitive proxy
29 Apr 19
DEFA14A
Additional proxy soliciting materials
29 Apr 19
DEFA14A
Additional proxy soliciting materials
15 Apr 18
DEF 14A
Definitive proxy
9 Apr 18
DEFA14A
Additional proxy soliciting materials
9 Apr 18
PRE 14A
Preliminary proxy
28 Mar 18
DEF 14A
Definitive proxy
10 May 17
Other
CT ORDER
Confidential treatment order
11 Mar 19
EFFECT
Notice of effectiveness
29 Jul 18
CORRESP
Correspondence with SEC
25 Jul 18
UPLOAD
Letter from SEC
25 Jul 18
EFFECT
Notice of effectiveness
7 Jun 17
CORRESP
Correspondence with SEC
5 Jun 17
CORRESP
Correspondence with SEC
4 Jun 17
CORRESP
Correspondence with SEC
1 Jun 17
UPLOAD
Letter from SEC
29 May 17
EFFECT
Notice of effectiveness
4 Aug 16
Ownership
SC 13G
VBI Vaccines / STATE STREET ownership change
11 Feb 21
SC 13G
VBI Vaccines / BlackRock ownership change
2 Feb 21
4
VBI Vaccines / Michel DeWilde ownership change
1 Feb 21
4
VBI Vaccines / Avi Mazaltov ownership change
1 Feb 21
4
VBI Vaccines / Blaine H. McKee ownership change
29 Jan 21
4
VBI Vaccines / Francisco Diaz-Mitoma ownership change
29 Jan 21
4
VBI Vaccines / Damian Braga ownership change
29 Jan 21
4
VBI Vaccines / Nell Beattie ownership change
29 Jan 21
4
VBI Vaccines / Christopher McNulty ownership change
29 Jan 21
4
VBI Vaccines / Joanne Cordeiro ownership change
29 Jan 21
Reddit threads
Daily Plays - April 12, 2021
12 Apr 21
$NIO closed last week right at a critical resistance extending from mid July 2020. If it fails to breakout, can test support of channel (31-32), but breakout seems imminent, especially after posting great March sales exceeding guideline __________ $DJI $DIA $SPX $SPY $NDX $QQQ $TSLA $LI $XPEV $CCIV
3 Apr 21
Daily Advice Thread - All basic help or advice questions must be posted here.
24 Mar 21
Daily Plays - March 19, 2021
19 Mar 21
What Are Your Moves Tomorrow, March 18, 2021
17 Mar 21
[SNGX] Good news just in, and my personal opinion!📈📈
16 Mar 21
Frequency Therapeutics - A sleeping biotech giant, about to wake from its slumber
15 Mar 21
[CHEK] Check Cap receives FDA Approval!
15 Mar 21
Favorite Stock/ETF
13 Mar 21
CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates Against COVID-19 Variants
10 Mar 21